Overview

Dasatinib In Waldenström Macroglobulinemia

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations

Phase:

Phase 1

Details

Lead Sponsor:

Jorge J. Castillo, MD

Collaborator:

Bristol-Myers Squibb

Treatments:

Dasatinib